Page 16 - 2 Director Reports (Annexure) 2021.cdr

62-63

Vildagliptin, Alogliptin of 'Gliptin' series and The Diagnostics Devices business has been making Vaccine manufacturers are the main pharmaceutical identified in the crisis which could have resulted in much
Empagliflozin, Dapagliflozin Propanediol, Amorphous rapid growth over last many years. During the past many sector beneficiaries from the COVID-19 crisis, though more disruption to the global healthcare sector.
Dapagliflozin, Canagliflozin Hemihydrate of 'Gliflozin' years, the Home Diagnostics business has made other sub-sectors – such as diagnostics, over-the counter Further industry also faced challenge in reliance on face-
series are also produced in the Baddi facility to cater the humongous growth in its sales revenue and captured (OTC) drug and medical-product manufacturers - are
to-face visits between doctors and, from the commercial
requirement of various customers for formulation top position in Blood Glucose and Blood Pressure also beneficiaries of efforts to combat the pandemic and
standpoint, the sales staff of drug makers marketing
development and for the patent free countries. Monitoring business. It is fully geared up to grab the all the consequences of full and partial lockdowns to reduce
newly approved treatments, or, from the healthcare
the opportunities in point of care business, wherein its spread.
The company is also focusing on another new perspective, with patients from the point of view of
therapeutic category i.e., Anti-Depressant drugs like people will get to know about body parameters from The pharmaceutical companies continue to focus on hospital-based drug administration. The Covid-19 crisis
comforts of their home and without moving out of their
Brexpiprazole and Anti-Ulcerative drug like Vonoprazan faster growing treatment areas which are less has shown the need for greater adaptability, flexibility
houses.
Fumarate, are in advance stage of development in the vulnerable to fierce competition such as immune and reforms in this crucial interface in the sector. New
R&D. Apart from this, another complex molecules The home devices business has been recording oncology and rare diseases. Pricing pressure further trends of digitisation and e-healthcare services to
'Vortioxetine Hydrobromide' of Anti-Depressant series tremendous growth over last many years and hold good intensifies in mass market, less innovative segments support patient monitoring at home will be a welcome
was developed and transferred its technology to plant fortune in the coming years. The customers continue to such as cardiovascular or diabetes. change to less flexible pre-Covid practices.
and its USDMF filing is planned for the current year. DMF repose confidence in our branded product portfolio and
Several companies have developed or are close to A new realisation is also drawn from the current
filing of another molecule Febuxostat of Anti-Gout the company hopes to record exponential growth in the
developing and distributing partly innovative exploratory pandemic that the pharma companies which have
category has also been planned for the current year. The coming years.
new vaccines in record time. Governments have been successfully concentrated on a few treatment areas like
collaborative project is also going on with NIPER Mohali BRAND SHARING AND PRODUCT CONTRACT ready to help, given the importance of the vaccines for oncology, immunology and rare diseases, partly through
for use of enzyme catalyst for cost effectiveness for the
MANUFACTURING (PCM) public health. They have poured large sums of money targeted acquisitions. The strategy of focusing on high-
synthesis of intermediates of various API's such as into the vaccine sector, in various forms. The vaccine growth medical areas, now complemented by vaccines,
Atorvastatin Calcium, Rosuvastatin calcium & Sitagliptin The brand sharing has not registered any growth developers in Europe and the US benefited from makes sense from multiple angles. The approach allows
Phosphate as a step forward towards green chemistry however contract manufacturing business did record a investment incentives and grants - as well as massive companies to avoid more crowded treatment areas with
initiative to be eco-friendly. growth of over 10% in its annual revenues. government pre-orders for which they received strong pricing pressure like diabetes or cardiovascular
Formulation's business was hit on account of
The company was granted Two process/ polymorph customer deposits - as governments increased spending drugs. The approach also enables them to realise
unavoidable situations created by pandemic COVID-19.
patents for Fexofenadine and Rosuvastatin during the on healthcare in general. significant growth and higher prices in a generally more
Your company has made its present felt across most of
year and other two patents for Sitagliptin and protected commercial environment given the narrow
the therapeutic areas due to its brand image and quality If the industry can use this opportunity to position itself as
Rosuvastatin are likely to be granted. The company has product delivery. a partner of governments and efficient “rescuer of range of competitors.
filed Eleven new patent applications for Novel society,” it is believed that this might unlock further On account of increased focus on the value of
processes/ New Polymorphs for Vortioxetine The company is putting up all its energies for the growth significant growth potential – and possibly less price medications the pharmaceutical companies are more
Hydrobromide, Amorphous/ Crystalline Empagliflozin, and expansion of its Diagnostics, Formulation and OTC regulation in the future. concerned than ever about ensuring research and
Amorphous/ Crystalline Linagliptin, Amorphous/ business. development hits the intended target. There is an effort
Crystalline Edoxaban, Amorphous Apixaban, OPPORTUNITIES AHEAD The rare disease or orphan drug market is projected to to achieve greater effectiveness and efficiency to meet
Brexpiprazole, saroglitazar etc. grow by a compound annual growth rate of 10.8% until
There has been a tremendous amount of growth in the 2026, much above the underlying pharma market. the needs of patients while also protecting the bottom
FORMULATIONS AND HOME HEALTH pharmaceutical industry in recent years, and the outlook line. Now a research is designed to identify medications
DIAGNOSTICS continues to be positive for 2021-2022. This is partly due OUTLOOK ON THREATS, RISKS AND CONCERNS that can improve the experience and quality of life for
The company has registered huge growth of more than to numerous compounds that are currently in the latter While the end of the pandemic may be in sight, it is not patients in a way that's more meaningful. This has
70% in home diagnostics devices business though stages of clinical development, coupled with hundreds of over yet. COVID-19 case numbers are on the rise required pharmaceutical companies to examine their
formulation business recorded a drop in its annual new products with approvals anticipated in 2021-2022 globally and major outbreaks continue to impact research and development practices to ensure they are
revenues during the year. The Diagnostics Devices and beyond. This happens to be a level of countries like India. It is likely that we will not even know refined and focused.
business of the company has made deep in roads into pharmaceutical production that is not customary and what recovery will look like until later in the year, when For businesses that can weather the last few months of
domestic Blood sugar measuring business as well Blood has not occurred for about a decade. The industry will vaccines are more widely available worldwide. lower-than-average demand, the future looks good.
pressure monitoring devices business. The Blood sugar continue to benefit from favourable demographic and The lingering impacts of COVID-19 will continue to have Some industry observers predict the pharmaceutical
measuring business as well Blood pressure monitoring lifestyle factors, innovations, and a diminishing threat a serious impact on the industry through the end of the sector will be back on track for rapid growth, as it was
devices business have recorded a compounded annual from expiring patents in addition to the shot in the arm year, in part because reduced consumer confidence pre-pandemic. With factors such as an aging global
growth rate (CAGR) of 40.68% and 42.54% respectively for the whole sector from the COVID-19 pandemic means lower than usual demand for pharmaceuticals. In population, increased prevalence of chronic conditions
during last 4 years. On overall basis, during these 4 whose impact goes beyond the vaccines segment. addition, customer purchasing power may remain low and the development of new drug therapies to
years, the devices business has recorded a compounded Healthcare awareness among large parts of the global as unemployment continues to be a challenge around encourage growth as the pandemic recedes and the
annual growth rate (CAGR) of 40.62%. The company population has significantly increased in the course of the world. economy recovers.
has cumulatively sold 600 million Gluco Strips as on 2020, triggered by the coronavirus pandemic, which will The initial stage of the Covid-19 crisis early in 2020 Upcoming patent cliffs will be bad news for some major
close of current year. Gluco monitors installations have underpin the sector's robust sales growth, set to run abruptly highlighted the danger of being dependent on pharmaceutical manufacturers, but good news for
cross 5 million as on date. Formulation's business lost ahead of economic growth in many countries. only one or very few suppliers. However, the risk of companies wanting to develop generic pharmaceuticals
some of its revenues on account of restriction imposed Demographic and lifestyle factors – such as ageing individual companies' over-dependence on single or and consumers in search of lower prices on medicine.
by COVID-19 curfew and not enough doctor's populations, diet-related illnesses in developed limited supplier suppliers did not materialise, but, in the
prescription being generated as doctors abstained from countries, growing prosperity in emerging markets – are larger scheme of things, it was one of the factors To emerge as a winner in the post-pandemic world, the
operating from their clinics. also crucial factors supporting sales growth. Indian industry needs to continue building on its strength